COVID-19 has dramatically changed what was already a rapidly evolving market for pharmaceuticals. As the pandemic drives rising healthcare costs and rapid provider consolidation, the pharmaceutical industry is looking for new ways to provide access to its products, particularly direct employer engagement.
When this crisis has passed, there will be a significant opportunity for manufacturers to communicate and collaborate with employers and help them navigate changes that have occurred over the past year. Economic considerations will be increasingly important for employers during benefit decision-making as they demand greater clinical value. To succeed, drug manufacturers seeking a competitive advantage through employer engagements and partnerships should act now, invest wisely and be patient.
This paper examines how this moment is an opportunity for manufacturers to engage employers, demonstrate the clinical and economic value of their portfolio, and rebuild trust.
Download the White Paper Below.